Star Metro - Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

NYSE - LSE

RBGPF	0.25%	68.32	$
CMSD	0.36%	22.23	$
NGG	-0.31%	82.59	$
RIO	-0.9%	93.58	$
RYCEF	1.11%	19.9	$
BCC	-0.86%	75.28	$
JRI	0.84%	13.11	$
BCE	-2.64%	20.87	$
GSK	-1.07%	53.09	$
RELX	1.05%	32.27	$
AZN	-2.62%	190.16	$
VOD	-0.54%	13.08	$
BTI	-0.5%	61.46	$
BP	-0.03%	37.39	$
CMSC	0.32%	22.06	$

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

BOULEVARD 17.06.2025

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Click here to register

Text size:

SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 18, 2025 at the Emerging Growth Conference.

Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference

When: Wednesday, June 18, 2025 from 9:40 - 10:10 AM Eastern Time

Where: Online (Click Here)

Registration link for conference: Click Here

Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the June 2025 Emerging Growth Conference. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

X.Boucher--SMC

Featured

Death toll from China storms rises to 15, hundreds injured

The death toll from devastating storms in parts of China rose to 15 on Tuesday, with hundreds more injured and tens of thousands evacuated, state media reported, as President Xi Jinping urged "all out" rescue efforts.

France's Le Pen faces pivotal ruling in race for president

France's far-right chief Marine Le Pen is bracing for a key verdict on Tuesday that will determine if she can run in next year's presidential elections, when her party has its best chance yet of winning power.

How US is using cash and threats to dump migrants in Africa

It began with threats of US visa bans on a swathe of African nations. Then Washington started to scatter migrants from all over the world to various corners of the continent, often with cash sweeteners for their governments.

Polaris Announces Execution of Mixed Investment Agreement for the Three Mexico Projects

TORONTO, ON / ACCESS Newswire / July 7, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce that, further to its press release dated June 8, 2026, it has reached another important milestone in the development of its three renewable energy projects selected under Mexico's Comisión Federal de Electricidad ("CFE") Mixed Development Program (the "Mixed Program").